TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Several other analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $9.00.

TuHURA Biosciences Stock Up 9.8%

HURA opened at $3.15 on Wednesday. The firm has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $1.60. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $4.44. The company has a market capitalization of $200.28 million, a PE ratio of -5.00 and a beta of -0.32.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Institutional Trading of TuHURA Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after acquiring an additional 307,260 shares during the period. Deutsche Bank AG increased its position in shares of TuHURA Biosciences by 209.8% during the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after acquiring an additional 54,051 shares during the period. New York State Common Retirement Fund purchased a new position in shares of TuHURA Biosciences during the second quarter worth approximately $97,000. Goldman Sachs Group Inc. purchased a new position in shares of TuHURA Biosciences during the fourth quarter worth approximately $30,000. Finally, Marshall Wace LLP purchased a new position in shares of TuHURA Biosciences during the second quarter worth approximately $79,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

TuHURA Biosciences News Summary

Here are the key news stories impacting TuHURA Biosciences this week:

• Positive Sentiment: Brookline Capital Markets sharply raised FY2026 and FY2027 EPS forecasts (FY2026 from ($0.59) to ($0.38); FY2027 from ($0.58) to ($0.36)) and also improved FY2028 to ($0.30) from ($0.44) — a material reduction in projected losses that likely underpins investor buying. Article Title
• Positive Sentiment: Zacks Research raised its FY2026 and FY2027 EPS estimates (FY2026 from ($0.55) to ($0.48); FY2027 from ($0.58) to ($0.51)), reinforcing the view that analyst expectations for future losses are moderating. Article Title
• Neutral Sentiment: Brookline published quarterly forecasts for 2026 showing ongoing negative EPS each quarter (Q1: ($0.10); Q2–Q4: ($0.09)), so while estimates improved year-over-year, the company is still expected to remain unprofitable near-term — a reminder this is a recovery/turnaround story rather than near-term profitability. Article Title

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.